Alpha Tau(DRTS) - 2024 Q4 - Annual Report

Exhibit 99.1 Alpha Tau Announces Full Year 2024Financial Results and Provides Corporate Update - Interim results from three trials exploring the use of Alpha DaRT in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurre ...